XWPharma
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3 Lagoon Dr Ste 160, Redwood City, Calif...Phone Number
(650) 885-9682Website
www.xwpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About XWPharma
XWPharma is a clinical stage biopharmaceutical company focused on developing innovative therapeutics for neurodegenerative diseases, psychiatric disorders, and pain management. The company employs novel platform chemistry and time-regulated neurobiology to create effective treatments that address significant unmet medical needs. Their pipeline includes investigational drugs targeting conditions such as narcolepsy, major depressive disorder, and chronic pain, aiming to improve patient outcomes and quality of life. XWPharma's therapies are designed for high-value commercial markets, ensuring favorable reimbursement and market access.Explore more
XWPharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is XWPharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when XWPharma launches new products
XWPharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at XWPharma
Check out if XWPharma is spiking on competitors!
Check if XWPharma has recently received funding, and reach out quickly before it becomes old news!
Click to see if XWPharma had a recent Job posting/layoffs
Funding: Get notified immidiatlly once XWPharma has new funding data
Earning: See what the market has to say on XWPharma recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to XWPharma
Compare insights from companies similar to XWPharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
<$5M
2005
CL
Cynthia LevinthalPrincipal Consultant. Neural Stem Cell Therapies. Clinical Trials
Company Profile Activity
Activity Insights
XWPharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
XWPharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about XWPharma.
XWPharma financials insights
Gather financial insights about XWPharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$5.5M
2017
Series B
$17M
2020
Series C
$40M
XWPharma Tech Stack
A closer look at the technologies used by XWPharma
Most Recent Scoops
Lateral Move
Executive Move
Lateral Move
New Hire
Executive Move
New Hire
Funding
Funding
XWPharma News & Media
Avance Clinical Client News: XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain
ADELAIDE, AUS, Oct 19, 2021 - (ACN Newswire) - Avance Clinical, the largest premium Australian CRO for international biotechs, is pleased to share the news that its client XWPharma Ltd. has announced dosing of subjects in its first-in-human study evaluating XW10508, the Company's novel, patented, glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy for the treatment of treatment-resistant depression and chronic pain. Avance Clinical is an award-winning AXWPharma Announces Abstract for XW10172 Accepted for Presentation at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting
Data to establish safety, tolerability, and once-nightly pharmacokinetics of XW10172 for treatment of sleep disorders associated with neurodegenerative diseases, including Parkinson’s disease and narcolepsy Data to establish safety, tolerability, and once-nightly pharmacokinetics of XW10172 for treatment of sleep disorders associated with neurodegenerative diseases, including Parkinson’s disease and narcolepsyXWPharma Names Glen Giovannetti to Board of Directors
New Board Member Brings Extensive Experience in Financial Oversight and Governance in the Life Sciences Industry as Company Advances its Pipeline of Novel CNS Therapeutics, Preparing for Future Stages of Growth and Development New Board Member Brings Extensive Experience in Financial Oversight and Governance in the Life Sciences Industry as Company Advances its Pipeline of Novel CNS Therapeutics, Preparing for Future Stages of Growth and DevelopmentXWPharma Names Michael M. Morrissey, PhD to Board of Directors
Appointment Adds Senior Biopharma Operational Expertise to Board Oversight as Company Advances its Pipeline of Novel CNS Therapeutics in Research and Clinical Development Appointment Adds Senior Biopharma Operational Expertise to Board Oversight as Company Advances its Pipeline of Novel CNS Therapeutics in Research and Clinical Development
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding XWPharma
Sign Up For FreeTo access detailed company insights
XWPharma is a clinical stage biopharmaceutical company focused on developing innovative therapeutics for neurodegenerative diseases, psychiatric disorders, and pain management. The company employs novel platform chemistry and time-regulated neurobiology to create effective treatments that address significant unmet medical needs. Their pipeline incl... Read More
